What Do Analysts Recommend for United Therapeutics?

Based on the recommendations of 14 brokerage firms in a Bloomberg survey, 23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.” Only 7.7% of the analysts rated United Therapeutics a “sell.” To learn more about the reduced analyst confidence and depressed valuation multiples for United Therapeutics, please refer to How Does United Therapeutics Compare with Peers on Valuation?

The consensus 12-month target price for United Therapeutics is ~$128.67, which represents a rise of approximately 16.2% from the stock’s last price of $110.86 on July 18, 2016. If the company’s share price manages to surpass this price target, it may also boost the iShares S&P Mid-Cap 400 Growth ETF (IJK). United Therapeutics makes up about 0.69% of IJK’s total portfolio.

Based on a Bloomberg survey of 14 broker firms, Ionis Pharmaceuticals (IONS) received “buy” recommendations from 38.5% of firms and “hold” recommendations from 53.8% of firms. Only 7.7% of firms have rated Ionis Pharmaceuticals as a “sell.” The consensus 12-month target price for Ionis Pharmaceuticals is ~$32.38, which represents a rise of 16.9% from the stock’s last price of $27.69 on July 18, 2016.

Among the 28 brokerage firms surveyed by Bloomberg for Regeneron (REGN), 51.9% gave it a “buy” while 44.4% gave it a “hold” recommendation. Only 3.7% of the surveyed firms rate Regeneron a “sell.” The consensus 12-month target price for Regeneron is ~$466.82, which represents a rise of 22.4% from the stock’s last price of $381.54 on July 18, 2016.

Based on the recommendations of 18 broker firms in a Bloomberg survey, Incyte (INCY) received “buy” recommendations from 88.9% of firms and “hold” recommendations from 11.1% of firms. None of the firms rated Incyte a “sell.” The consensus 12-month target price for Incyte is ~$92.20, which represents a rise of 9.6% from the stock’s closing price of $85.54 on July 18, 2016.